Cargando…
YAP increases response to Trastuzumab in HER2-positive Breast Cancer by enhancing P73-induced apoptosis
The role of the Yes-associated protein (YAP) in oncogenesis and progression of breast cancer remains controversial. Meanwhile, development of therapeutic resistance to trastuzumab, a common breast cancer treatment administered after chemotherapy, is a significant challenge in the treatment of HER2-p...
Autores principales: | Cao, Lanqing, Yao, Min, Sasano, Hironobu, Sun, Ping-Li, Gao, Hongwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545685/ https://www.ncbi.nlm.nih.gov/pubmed/33046997 http://dx.doi.org/10.7150/jca.48535 |
Ejemplares similares
-
The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer
por: González-Alonso, Paula, et al.
Publicado: (2020) -
The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition
por: Shi, Jiaolong, et al.
Publicado: (2018) -
Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022) -
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014) -
Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)